Abstract
“Looming patent expiry a major force in driving valuation”
Drugs with annual sales totalling over US$86 B in 2007 are due to go off
patent by 2012. Therefore, the application of novel drug delivery technologies
to such existing therapeutics is an attractive means of prolonging the
commerical viability of marketed drugs.
Technologies are more difficult to value than products in clinical development
because the technical risks or success rates are less well documented, and
costs and timescales are less predictable.
It is very important to benchmark when valuing technologies and to have a
thorough understanding of the risks and rewards.
This new PharmaDealsR Report, covers the range of strategies and offerings
available to the deal maker, and is vital for understanding growth and
survival in volatile markets.
| 
View Cart
